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Abstract
To establish a more effective therapeutic strategy
against advanced bladder cancer, we investigated
the effects of combined treatment with antisense
(AS) oligodeoxynucleotide (ODN) targeting the anti-
apoptotic gene clusterin and adenoviral-mediated
p53 gene transfer (Ad5CMV-p53) using the human
bladder cancer KoTCC-1 model. Clusterin expression
in KoTCC-1 cells was highly upregulated by Ad5CMV-
p53 treatment; however, AS clusterin ODN treatment
further suppressed clusterin expression in KoTCC-1
cells after Ad5CMV-p53 treatment. AS clusterin ODN
treatment synergistically enhanced the cytotoxic effect
of Ad5CMV-p53, and DNA fragmentation characteristic
of apoptosis was observed only after combined treat-
ment with AS clusterin ODN and Ad5CMV-p53, but not
after treatment with either agent alone. Administration
of AS clusterin ODN and Ad5CMV-p53 into nude mice
resulted in a significant inhibition of KoTCC-1 tumor
growth as well as lymph node metastases compared
to administration of either agent alone. Furthermore,
combined treatment with AS clusterin ODN, Ad5CMV-
p53, and cisplatin completely eradicated KoTCC-1
tumors and lymph node metastases in 60% and 100%
of mice, respectively. These findings suggest that
combined treatment with AS clusterin ODN and
Ad5CMV-p53 could be a novel strategy to inhibit
bladder cancer progression, and that further additional
use of a chemotherapeutic agent may substantially
enhance the efficacy of this combined regimen.
Neoplasia (2005) 7, 171–179
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Introduction
To date, cisplatin-based combination chemotherapy has
been the mainstay of treatment for patients with advanced
bladder cancer, and it is at least palliatively effective.
However, the efficacy of cisplatin-based combination che-
motherapy is limited due to de novo drug resistance, or the
development of cellular-resistant phenotype during treatment;
therefore, there has been no study demonstrating the signifi-
cant prognostic benefit of this therapy for patients with
advanced disease [1,2]. Accordingly, novel therapeutic strate-
gies targeting molecular mechanisms mediating resistance to
conventional treatments must be developed to achieve a sig-
nificant impact on the survival of advanced bladder cancer
patients.
Gene transfer techniques may provide novel therapeutic
strategies for a variety of malignancies. Among them, repli-
cation-deficient adenoviral vectors, which are capable of
highly efficient infection in target cells, have been regarded
as one of the most attractive tools [3]. To date, a number of
studies have demonstrated marked growth-inhibitory effects of
adenoviral-mediated gene therapy of wild-type p53 on various
types of tumor growth both in vitro and in vivo, including
bladder cancer, through the induction of apoptotic cell death;
based on promising findings of these preclinical studies,
several clinical trials of p53 gene therapy have been carried
out [4–6]. Recent studies, however, reported that overexpres-
sion of antiapoptotic genes inhibits the therapeutic efficacy of
adenoviral-mediated p53 gene transfer (Ad5CMV-p53) [7,8],
suggesting that it would be necessary to consider the addi-
tional treatment using another type of adequate agent if
adenovirus p53 vectors are used for patients expressing high
levels of antiapoptotic genes.
Clusterin, also known as testosterone-repressed prostate
message-2, sulfated glycoprotein-2, or apolipoprotein J, was
first isolated from ram rete testes fluid, and has been shown
to be implicated in several pathophysiological processes,
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including tissue remodeling, reproduction, lipid transport,
and apoptotic cell death [9]. Because clusterin expression is
highly upregulated in various benign and malignant tissues
undergoing apoptosis, clusterin was initially regarded as a
marker for cell death [10,11]. Recent studies, however,
reported conflicting findings that clusterin acts as a cell
survival gene through the inhibition of apoptosis induced
by a wide variety of stimuli [12–16]. Our previous studies
demonstrated that overexpression of clusterin is closely as-
sociated with disease progression and recurrence in pa-
tients with bladder cancer [17], and that antisense (AS)
oligodeoxynucleotide (ODN) therapy targeting clusterin gene
enhances the efficacies of cytotoxic chemotherapy, resulting
in an inhibition of the growth and metastasis of bladder
cancer cells [18,19]. However, because numerous genes
mediate tumor progression, inhibition of a single target gene
with AS technology is likely insufficient to completely sup-
press tumor progression. Although there have not been any
reports demonstrating complete eradication of established
tumors in vivo using AS ODN alone, combined use of AS
ODN with another ODN targeting a different gene or an other
type of therapeutic modality, such as chemotherapeutic
agents and radiotherapy, has been shown to induce more
potent antineoplastic effects in some tumor model systems
[14–16,20].
This study investigated whether apoptotic cell death
induced by Ad5CMV-p53 is synergistically enhanced by AS
clusterin ODN treatment, and determined whether combined
treatment with Ad5CMV-p53 and AS clusterin ODN inhibits
tumor growth and metastasis in the human bladder KoTCC-1
tumor model.
Materials and Methods
Tumor Cell Line
The human bladder cancer cell line KoTCC-1 was estab-
lished in our laboratory [8] and was maintained in RPMI 1640
(Life Technologies, Inc., Gaithersburg, MD) supplemented
with 10% fetal calf serum.
Chemotherapeutic Agent
Cisplatin, a generous gift from Nippon Kayaku Co.
(Tokyo, Japan), was dissolved in PBS at 1 mg/ml and diluted
in medium before each experiment.
Adenovirus Vectors
Replication-deficient recombinant adenovirus vectors [8]
were used in this study (i.e., Ad5CMV-p53 expresses the
wild-type human p53 under the control of the human cyto-
megalovirus promoter, and Ad5CMV-Luc–encoding Lucifer-
ase gene was used as a control vector). Adenoviruses were
propagated in human embryonic kidney 293 cells, which
contain E1 and are thus highly permissive of the replication
of the E1 replication-deficient adenovirus. It was stored as
previously reported, and the viral infection titers were deter-
mined by plaque assays [8].
AS Clusterin ODN
Phosphorothioate ODNs used in this study were gen-
erously supplied by Dr. Brett P. Monia (Isis Pharmaceuti-
cals, Carlsbad, CA). The sequence of AS clusterin ODN
corresponding to the human clusterin translation initiation
site was 5V-CAGCAGCAGAGTCTTCAT-3V. Two-base clus-
terin mismatch (MM) ODN (5V-CAGCAGCAGAGTATTTAT-
CAT-3V) was used as the control. ODNswere diluted in 10mM
Tris (pH 7.4) and 1 mM ethylenediaminetetraacetic acid
(EDTA) and kept at 20jC.
Treatment of Cells with ODN
KoTCC-1 cells were treated with various concentrations
of ODN after a preincubation for 20 minutes with 4 mg/ml
lipofectin (Life Technologies, Inc.) in serum-free OPTI-MEM
(Life Technologies, Inc.). Four hours later, the medium
containing ODN and lipofectin was replaced with the stan-
dard culture medium described above.
Northern Blot Analysis
Total RNA was isolated from cultured KoTCC-1 cells by
the acid – guanidium thiocyanate – phenol – chloroform
method. Electrophoresis, hybridization, and washing condi-
tions were carried out as previously reported [14]. Human
clusterin and GAPDH cDNA probes were generated by
reverse transcription polymerase chain reaction (RT-PCR)
from total RNA of human kidney using primers 5V-AAG-
GAAATTCAAAATGCTGTCAA-3V (sense) and 5V-ACAGA-
CAAGATCTCCCGGCACTT-3V (antisense) for clusterin,
and 5V-TGCTTTTAACTCTGGTAAAGT-3V (sense) and 5V-
ATATTTGGCAGGTTTTTCTAGA-3 V (antisense) for
GAPDH. The density of bands for clusterin was normalized
against that of GAPDH by densitometric analysis.
Real-Time RT-PCR
Total RNA was isolated as described above, and 1 mg of
each total RNA was reverse-transcribed using an Oligo dT
and Superscript preamplification system (Life Technologies,
Inc.). To examine the expression levels of clusterin, real-time
quantitative PCR was performed using Sequence Detector
(ABI PRISM 7700; PE Applied Biosystems, Foster City,
CA). Selected sequences of primers and probes are as
follows: 5V-GAGCAGCTGAACGAGCAGTTT-3V (sense), 5V-
CTTCGCCTTGCGTGAGGT-3V (antisense), and 5V-
ACTGGGTGTCCCGGCT-3V (probe) for clusterin; and
5V-GAAGGTGAAGGTCGGAGTC-3V (sense), GAPDH 5V-
GAAGATGGTGATGGGATTTC-3V (antisense), and 5V-
CAAGCTTCCCGTTCTCAGCC-3V (prove) for GAPDH.
The TaqMan probes consisted of an ODN with a 5V
FAM reporter dye and a 3V TAMRA quencher dye. Each
cDNA was analyzed by quantitative PCR in a 50-ml
volume using Master Mix (PE Applied Biosystems). The
condition of thermal cycling was 50 cycles of amplification
consisting of 15 seconds at 95jC and 1 minute at 60jC.
Real-time quantitation was performed using TaqMan
assay according to the manufacturer’s instruction. After
the generation of a real-time amplification plot based on
the normalized fluorescence signal, the threshold cycle
(CT) was determined. The CT was then used for kinetic
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analysis and was proportional to the initial number of
target copies in the sample. The starting quantity of a
sample was calculated after comparison of the CTs of a
serial dilution of a positive control. Transcripts of the
GAPDH were also quantified as an internal reference,
and the quantification value of clusterin mRNA was
described as each value relative to GAPDH mRNA.
In Vitro Cell Growth Assay
The in vitro growth-inhibitory effects of AS clusterin
ODN and/or Ad5CMV-p53 on KoTCC-1 cells were
assessed using MTT (Sigma Chemical Co.) as described
previously [8]. Briefly, 1  104 cells were seeded in each
well of 96-well microtiter plates and allowed to attach
overnight. Cells were then treated once daily with various
concentrations of ODN for 2 days. Following ODN treat-
ment, cells were treated with various concentrations of
Ad5CMV-p53. After 48 hours of incubation, 20 ml of 5 mg/
ml MTT in PBS was added to each well, followed by incu-
bation for 4 hours at 37jC. The formazan crystals were
dissolved in DMSO. The optical density was determined
with a microculture plate reader (Becton Dickinson Lab-
ware, Lincoln Park, NJ) at 540 nm. Absorbance values
were normalized to the values obtained for the vehicle-
treated cells to determine the percentage of surviving cells.
Each assay was performed in triplicate.
DNA Fragmentation Analysis
Nucleosomal DNA degradation was analyzed as
described previously with minor modifications [8]. Briefly,
1  105 KoTCC-1 cells were seeded in 5-cm culture dishes
and allowed to adhere overnight. After treatment with ODN
plus Ad5CMV-p53 using the same schedule described
above, cells were harvested and then lysed in a solution
containing 100mMNaCl, 10mM Tris (pH 7.4), 25mMEDTA,
and 0.5% SDS. After centrifugation, the supernatants were
incubated with 300 mg/ml proteinase K for 5 hours at 65jC
and extracted with phenol–chloroform. The aqueous layer
was treated with 0.1 vol of 3 M sodium acetate, and the DNA
was precipitated with 2.5 vol of 95% ethanol. Following
treatment with 100 mg/ml RNase A for 1 hour at 37jC, the
sample was electrophoresed on a 2% agarose gel and
stained with ethidium bromide.
Measurement of Apoptosis
The nucleosomal DNA degradation was quantified by
Cell Death Detection ELISA kit using antihistone antibody
(Roche, Mannheim, Germany) as described previously [21].
Briefly, 1  105 KoTCC-1 cells were seeded in 5-cm culture
dishes and allowed to adhere overnight. After treatment with
ODN and/or Ad5CMV-p53 under the same schedule as
described above, cells were harvested and then assays were
performed in triplicate according to the manufacturer’s
instruction.
Assessment of In Vivo Tumor Growth
Athymic nude mice (Balb/c nu/nu females, 6–8 weeks
old) were purchased from CLEA Japan, Inc. (Tokyo, Japan)
and housed in a controlled environment at 22jC on a 12-hour
light/12-hour dark cycle. Animals were maintained in accord-
ance with the NIH Guide for the Care and Use of Laboratory
Animals. Each experimental group consisted of 10 mice.
KoTCC-1 cells were trypsinized, washed twice with PBS,
and injected subcutaneously with 1 106 cells in the flank, or
directly administered 1  106 cells into the bladder wall, as
previously described [8].
For the first set of experiments, 10 days after injection,
mice were randomly selected for treatment with AS clusterin
ODN plus Ad5CMV-Luc, MM control ODN plus Ad5CMV-
Luc, AS clusterin ODN plus Ad5CMV-p53, or MM control
ODN plus Ad5CMV-p53. After randomization, 10 mg/kg AS
clusterin or MM control ODN was injected intravenously once
daily into each mouse for 28 days, and 200 ml of adenovirus
vector (1  107 PFU/ml) was injected intratumorally or intra-
peritoneally into mice-bearing subcutaneous or orthotopic
tumors, respectively, twice a week for 2 weeks.
For the second set of experiments, 10 days after injection,
mice were randomly selected for treatment with AS clusterin
ODN, Ad5CMV-Luc plus cisplatin, MM control ODN,
Ad5CMV-Luc plus cisplatin, AS clusterin ODN, Ad5CMV-
p53 plus cisplatin or MM control ODN, and Ad5CMV-p53
plus cisplatin. After randomization, 10 mg/kg AS clusterin or
MMcontrol ODNwas injected intraperitoneally once daily into
eachmouse for 28 days, and 200 ml of adenovirus vector (1
107 PFU/ml) was injected intratumorally or intraperitoneally
intomice bearing subcutaneous or orthotopic tumors, respec-
tively, twice a week for 2 weeks, and 50 mg of cisplatin was
injected intravenously twice a week for 2 weeks.
Tumor volumewasmeasured every 5 days and calculated
by the formula: length  width  depth  0.5236 [20]. Eight
weeks after the injection of tumor cells in the bladder wall,
the mice were sacrificed and the presence of metastasis
was macroscopically examined in all abdominal and tho-
racic internal organs. Organs with metastases were re-
moved, and the number of surface metastatic nodules was
counted.
Statistical Analysis
A repeated-measures analysis of variance (ANOVA)
model was used to analyze the in vitro cytotoxic effects of
ODN and Ad5CMV-p53. Synergy of ODN and Ad5CMV-p53
was analyzed by calculating the fractional product parameter
according to the fractional product method. Other data were
analyzed by Student’s t test. The level of significance was
set at P < .05, and all statistical calculations were performed
using Statview 4.5 software (Abacus Concepts, Inc., Berke-
ley, CA).
Results
Changes in Clusterin mRNA Expression in KoTCC-1 Cells
after Treatment with Ad5CMV-p53 and/or AS Clusterin ODN
We initially showed the dose-dependent and sequence-
specific inhibition of clusterin mRNA expression in KoTCC-1
cells by treatment with AS clusterin ODN using Northern blot
analysis (Figure 1A). Treatment with 500 nM AS clusterin
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ODN decreased the clusterin mRNA level in KoTCC-1 cells
by more than 80% compared to that following treatment with
500 nM MM control ODN.
Real-time RT-PCR assay was used to analyze the effects
of Ad5CMV-p53 treatment on clusterin mRNA expression
in KoTCC-1 cells. As shown in Figure 1B, upregulation of
clusterin mRNA was induced in a dose-dependent manner
by Ad5CMV-p53 treatment at concentrations up to 100 PFU/
cell. Time course experiment showed that Ad5CMV-p53
treatment resulted in clusterin mRNA induction in KoTCC-1
cells peak by 96 hours after treatment and began decreasing
by 120 hours after treatment (Figure 1C).
It was then examined whether AS clusterin ODN treat-
ment further suppressed clusterin expression in KoTCC-1
cells treated by Ad5CMV-p53, which causes upregulation of
clusterin mRNA as described above. As shown in Figure 1D,
combined treatment with 500 nM AS clusterin ODN and 10 or
50 PFU/cell Ad5CMV-p53 decreased clusterin mRNA levels
by 90% or 93%, respectively, compared with 500 nM MM
control ODN and 10 or 50 PFU/cell Ad5CMV-Luc treatment.
Figure 1. Effects of AS clusterin ODN and/or Ad5CMV-p53 treatment on clusterin expression in KoTCC-1 cells. (A) KoTCC-1 cells were treated daily with AS
clusterin ODN or a two-base clusterin MM ODN for 2 days. Total RNA was extracted from cultured cells, and analyzed for clusterin and GAPDH levels by Northern
blotting. No Tx indicates untreated cells. (B) KoTCC-1 cells were treated with various doses of Ad5CMV-p53 for 48 hours; total RNA was then extracted and
analyzed for clusterin levels by real-time RT-PCR. As described in Materials and Methods section, the clusterin mRNA value was corrected by the corresponding
GAPDH mRNA value. Each column represents the mean value of three independent experiments with standard deviation. *Differs from control (P < .05) by
Student’s t test. **Differs from control (P < .01) by Student’s t test. (C) KoTCC-1 cells were treated with Ad5CMV-p53 at 50 PFU/cell for indicated intervals; total
RNA was then extracted and analyzed for clusterin levels by real-time RT-PCR. As described in Materials and Methods section, the clusterin mRNA value was
corrected by the corresponding GAPDH mRNA value. Each column represents the mean value of three independent experiments with standard deviation. *Differs
from control (P < .05) by Student’s t test. **Differs from control (P < .01) by Student’s t test. (D) KoTCC-1 cells were treated daily with 500 nM AS clusterin ODN or a
two-base clusterin MM control ODN for 2 days. Following exposure to Ad5CMV-p53 at 10 or 50 PFU/cell for 48 hours, total RNA was then extracted and clusterin
levels were analyzed by real-time RT-PCR. As described in Materials and Methods section, the clusterin mRNA value was corrected by the corresponding GAPDH
mRNA value. Each column represents the mean value of three independent experiments with standard deviation. *Differs from control (P < .01) by Student’s t test.
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Synergistic Induction of Growth Inhibition and Apoptosis by
Combined Treatment with Ad5CMV-p53 and AS Clusterin
ODN in KoTCC-1 Cells In Vitro
To examine whether downregulation of clusterin using AS
clusterin ODN treatment results in enhanced cytotoxicity
induced by Ad5CMV-p53, KoTCC-1 cells were treated with
various concentrations of AS clusterin ODN once daily for
2 days, and then incubated with various concentrations of
Ad5CMV-p53 for 2 days. As shown in Figure 2A, AS clusterin
ODN treatment significantly enhanced the sensitivity of
KoTCC-1 cells to Ad5CMV-p53 in a dose-dependent man-
ner, reducing the IC50 of Ad5CMV-p53 by more than 75%,
whereas MM control ODN had no effect. Dose-dependent
synergistic cytotoxicity between AS clusterin ODN and
Ad5CMV-p53 was also observed by increasing the concen-
tration of AS ODN when Ad5CMV-p53 dose was fixed at
10 PFU/cell (Figure 2B).
The DNA fragmentation assay was performed to compare
induction of apoptosis after treatment with 500 nM AS
clusterin ODN either alone or in combination with a sublethal
dose of Ad5CMV-p53 (10 PFU/cell). Using the same treat-
ment schedule described above, the characteristic apoptotic
DNA ladder was observed only after combined treatment with
AS clusterin ODN plus Ad5CMV-p53. We further evaluated
the effects of combined AS clusterin ODN plus Ad5CMV-p53
on apoptosis induction using an ELISA kit to quantitatively
measure fragmented DNA. After the same treatment sched-
ule described above, a significantly higher level of DNA
fragmentation was detected after combined treatment with
AS clusterin ODN and Ad5CMV-p53 (Figure 2D).
Figure 2. Effect of combined treatment with AS clusterin ODN and Ad5CMV-p53 on KoTCC-1 cell growth and apoptosis. (A) KoTCC-1 cells were treated daily with
500 nM AS clusterin ODN or MM control ODN for 2 days. Following ODN treatment, the medium was replaced with medium containing various doses of Ad5CMV-
p53. After 48 hours of incubation, the number of viable cells was determined by the MTT assay. Each data point represents the mean of triplicate analyses with
standard deviation. The cytotoxic effect of Ad5CMV-p53 on KoTCC-1 cells was significantly enhanced by AS clusterin ODN treatment (P < .01, by ANOVA). (B)
KoTCC-1 cells were treated daily with various concentrations of AS clusterin ODN or MM control ODN for 2 days, then incubated for 48 hours with medium alone or
medium containing Ad5CMV-p53 or Ad5CMV-Luc at 10 PFU/cell, and the number of viable cells was determined by the MTT assay. Each data point represents the
mean of three independent experiments with standard deviation. Treatment of KoTCC-1 cells with AS clusterin ODN significantly enhanced the sensitivity to
Ad5CMV-p53 (P < .05, by ANOVA). (C) After the same treatment schedule as described above, DNA was extracted from KoTCC-1 cells, electrophoresed in a 2%
agarose gel, and visualized by ethidium bromide staining and UV transillumination. (D) After the same treatment schedule as described above, DNA fragmentation
was quantitatively measured by Cell Death Detection ELISA kit using antihistone antibody. Each column represents the mean value of three independent
experiments with standard deviation. *Differs from control (P < .01) by Student’s t test.
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Inhibitory Effects of Combined Treatment with Ad5CMV-p53
and as Clusterin ODN on KoTCC-1 Tumor Growth and
Metastasis In Vivo
The antitumor effect of a regimen combining Ad5CMV-
p53 and AS clusterin ODN on the growth of subcutaneous
KoTCC-1 tumors was initially evaluated. Athymic nude mice
bearing KoTCC-1 tumors approximately 1 cm in the maximal
length were randomly selected for treatment as described
above. Mean tumor volume was similar in each of these
groups at the beginning of treatment. There was no signifi-
cant difference in changes in tumor volume in mice treated
with AS clusterin ODN plus Ad5CMV-Luc and that in mice
treated with MM control ODN plus Ad5CMV-Luc. Compared
with these two treatment groups described above, slight but
definitive inhibition of tumor growth was achieved by treat-
ment with MM control ODN plus Ad5CMV-p53, and com-
bined AS clusterin ODN and Ad5CMV-p53 therapy showed a
remarkable growth-inhibitory effect on subcutaneous tumor.
Fifty days after tumor injection of KoTCC-1 cells, the mean
tumor volume in mice treated with AS clusterin ODN plus
Ad5CMV-p53 was 75%, 75%, or 67% smaller than that in
mice treated with AS clusterin ODN plus Ad5CMV-Luc, MM
control ODN plus Ad5CMV-Luc, or MM control ODN plus
Ad5CMV-p53, respectively (Figure 3).
We subsequently examined the effects of the combined
regimen using a recently reported orthotopic injection (i.e.,
direct injection of tumor cells into bladder wall) model [8]
according to the treatment schedule described above. As
shown in Table 1, the combined treatment with AS clusterin
ODN and Ad5CMV-p53 potentially suppressed the tumor
progression after orthotopic injection of KoTCC-1 cells com-
pared to the other three treatment regimens (i.e., both the
weight of the primary KoTCC-1 tumor in the bladder wall and
the incidences of retroperitoneal lymph node metastasis,
mesenteric lymph node metastasis, and hemorrhagic ascites
in mice treated with combined AS clusterin ODN and
Ad5CMV-p53 were significantly lower than those in mice
treated with AS clusterin ODN plus Ad5CMV-Luc, MM con-
trol ODN plus Ad5CMV-Luc, or MM control ODN plus
Ad5CMV-p53).
Complete Eradication of KoTCC-1 Tumor In Vivo by
Combined Treatment with Ad5CMV-p53, AS Clusterin
ODN, and Cisplatin
We investigated whether it is possible to induce a more
substantial therapeutic effect on KoTCC-1 tumor growth by
further administration of cisplatin in addition to combined
regimen consisting of Ad5CMV-p53 and AS clusterin ODN.
Athymic nude mice bearing subcutaneous KoTCC-1 tumors
approximately 1 cm in the maximal length were randomly
selected for treatment as described above. Mean tumor
volume was similar at the beginning of treatment in each of
these groups. As shown in Figure 4, the combined treatment
with Ad5CMV-p53, AS clusterin ODN, and cisplatin signifi-
cantly inhibited the KoTCC-1 tumor growth compared with
those in the other three treatment groups, and KoTCC-1
tumors in 6 of 10 mice completely regressed by this com-
bined therapy. Furthermore, the development of lymph node
metastasis and hemorrhagic ascites was inhibited in all mice,
in which KoTCC-1 cells were orthotopically injected, after
combined treatment with Ad5CMV-p53, AS clusterin ODN,
and cisplatin (Table 2).
Discussion
With advances in the field of molecular biology, several novel
strategies based on the mechanism of malignant disease
progression have been developed as attractive alternation of
conventional approaches. For example, AS ODNs targeted
against specific genes playing key roles in neoplastic pro-
gression, including clusterin, have been investigated as
potential therapeutic agents [13–16,18,19,22,23], and some
of them have been tested in clinical trials [24,25]. Although
these findings suggest that ASODN could be a novel class of
powerful antineoplastic agents, downregulating a single tar-
get gene may likely be insufficient to achieve a complete
response against advanced disease. In addition, the useful-
ness of gene therapies introducing wild-type p53 has been
reported against a variety of malignant diseases including
bladder cancer [4–6]. Nevertheless, overexpression of anti-
apoptotic genes, such as bcl-2, in target tumor tissues, has
recently been shown to effectively disrupt the therapeutic
effect of the p53 gene therapy through the inhibition of
apoptotic cell death [7,8], suggesting the insufficiency of this
therapy as a single therapeutic method for advanced malig-
nant diseases. Therefore, it would be necessary to explore
the effects of combining different types of agents to produce
more substantial therapeutic benefits.
Figure 3. Effects of combined treatment with AS clusterin ODN plus
Ad5CMV-p53 on KoTCC-1 tumor growth. Mice bearing KoTCC-1 tumor were
randomly selected for treatment with AS clusterin ODN plus Ad5CMV-Luc,
MM control ODN plus Ad5CMV-Luc, AS clusterin ODN plus Ad5CMV-p53,
or MM control ODN plus Ad5CMV-p53. Ten days after tumor cell injection,
10 mg/kg AS clusterin ODN or MM control ODN was injected daily intra-
peritoneally for 28 days, and 200 l of Ad5CMV-p53 or Ad5CMV-Luc (1 
107 PFU/ml) was injected intratumorally twice a week for 2 weeks. Tumor
volume was measured every 5 days and calculated by the formula: length 
width  depth  0.5236. Each data point represents the mean tumor volume
in each experimental group containing 10 mice with standard deviation. Mean
tumor volume in mice treated with AS clusterin ODN plus Ad5CMV-p53
50 days after tumor injection was significantly smaller than that in mice
treated with other regimens (P < .001 by Student’s t test).
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Our recent studies, focusing on the role of clusterin in
bladder cancer, demonstrated that clusterin helps mediate
malignant progression of bladder cancer against apoptosis
induced by chemotherapeutic agent [17–19]. Considering
the findings described above, we evaluated the efficacy of
combined treatment of AS ODN targeting clusterin gene and
Ad5CMV-p53 using the human bladder KoTCC-1 tumor
model. We initially showed the remarkable upregulation of
the clusterin gene in KoTCC-1 cells after treatment with
Ad5CMV-p53. Although the molecular mechanism involved
in the upregulation of clusterin by apoptotic stimuli remains
largely unknown, this outcome is consistent with previous
studies demonstrating enhanced clusterin expression in
both benign and malignant tissues undergoing apoptosis
[10,11,13–16]. Hence, upregulation of the clusterin gene
may likely be an adaptive response to the introduction of
wild-type p53 gene, which helps the survival cell against p53-
dependent cell death signals. However, even after treatment
with Ad5CMV-p53, AS clusterin ODN significantly inhibited
clusterin expression in KoTCC-1 cells. Despite the lack of
growth inhibition by AS clusterin ODN alone, AS clusterin
ODN enhanced the cytotoxic effect of Ad5CMV-p53 on
KoTCC-1 cells, reducing its IC50 by more than 75%. We
further observed similar in vitro effects of Ad5CMV-p53 and
AS clusterin ODN treatment on two additional human blad-
der cancer HT1376 and UMUC3 cells (American Type
Culture Collection, Rockville, MD) to those on KoTCC-1 cells
(data not shown). These findings clearly showed that clus-
terin expression in bladder cancer is associated with a
phenotype resistant to Ad5CMV-p53– induced apoptosis;
therefore, targeted suppression of clusterin using AS ODN
increases the sensitivity of apoptotic stimuli inducing p53-
dependent apoptosis for bladder cancer.
Despite the initial response to conventional therapeutic
strategies for advanced bladder cancer, the development of
an acquired resistant phenotype is observed in the majority
of patients with advanced disease [1,2]. This phenome-
non could partially be explained by the fact that overexpres-
sion of antiapoptotic genes, including clusterin, in bladder
cancer cells helps mediate resistance to conventional treat-
ments through the inhibition of therapy-induced apoptosis
[6,18,19,26]. These findings suggest that the approach of
enhancing sensitivity to stimuli, which induce apoptotic cell
death, by suppressing the expression of the antiapoptotic
gene appears to be a more rational strategy for patients with
advanced bladder cancer rather than conventional treatment
options. Accordingly, based on the results of the present
in vitro experiments, we subsequently examined the in vivo
effects of combined treatment with AS clusterin ODN and
Ad5CMV-p53 on the growth and metastasis of KoTCC-1
cells. Consistent with the in vitro studies, a regimen combin-
ing AS clusterin ODN and Ad5CMV-p53 synergistically
inhibited the growth of subcutaneous KoTCC-1 tumors.
Table 1. Changes in Metastasis of KoTCC-1 Cell Injected Into the Bladder Wall of Nude Mice after AS Clusterin ODN and Ad5CMV-p53 Treatment.
Regimen* Incidence of Metastasis (%)
y
Retroperitoneal
Lymph Node
Metastasis
Intraabdominal
Lymph Node
Metastasis
Incidence of
Hemorrhagic
Ascites (%)z
Weight of
the Primary
Tumor (mg)
AS clusterin ODN + Ad5CMV-Luc 10/10 (100) 9/10 (90) 8/10 (70) 39.8 ± 8.5§
MM control ODN + Ad5CMV-Luc 10/10 (100) 9/10 (90) 9/10 (90) 40.9 ± 9.3
AS clusterin ODN + Ad5CMV-p53 3/10 (30)b 2/10 (20)b 1/10 (10)b 17.6 ± 6.1#
MM control ODN + Ad5CMV-p53 8/10 (80) 7/10 (70) 6/10 (60) 33.0 ± 8.7
*Ten days after the implantation of tumor cells, 10 mg/kg AS clusterin ODN or MM clusterin ODN was injected intraperitoneally once daily for 4 weeks, and 200 m1
of Ad5CMV-p53 or Ad5CMV-Luc was injected intraperitoneally twice a week for 2 weeks.
yNumber of mice with tumor per number of injected mice.
zNumber of mice with hemorrhagic ascites per number of injected mice.
§Mean ± standard deviation.
bThe incidence of metastasis or hemorrhagic ascites was significantly different from that in mice treated with other regimens (P < .05, chi-square analysis).
#The mean weight of the primary tumor was significantly different from that in mice treated with other regimens (P < .05, Student’s t test).
Figure 4. Effects of combined treatment with AS clusterin ODN, Ad5CMV-
p53, and cisplatin on KoTCC-1 tumor growth. Mice bearing KoTCC-1 tumor
were randomly selected for treatment with AS clusterin ODN, Ad5CMV-Luc
plus cisplatin, MM control ODN, Ad5CMV-Luc plus cisplatin, AS clusterin
ODN, Ad5CMV-p53 plus cisplatin, or MM control ODN, and Ad5CMV-p53
plus cisplatin. Ten days after tumor cell injection, 10 mg/kg AS clusterin ODN
or MM control ODN was injected daily intraperitoneally for 28 days; 200 ml of
Ad5CMV-p53 or Ad5CMV-Luc (1  107 PFU/ml) was injected intratumorally
twice a week for 2 weeks; and 50 mg of cisplatin was injected intravenously
twice a week for 2 weeks. Tumor volume was measured every 5 days and
calculated by the formula: length  width  depth  0.5236. Each data point
represents the mean tumor volume in each experimental group containing
eight mice with standard deviation. Mean tumor volume in mice treated with
AS clusterin ODN, Ad5CMV-p53, plus cisplatin 50 days after tumor injection
was significantly smaller than that in mice treated with other regimens (P <
.001 by Student’s t test).
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The combined regimen also significantly delayed disease
progression after orthotopic injection of KoTCC-1 cells
through suppression of primary tumor growth as well as
lymph node metastasis. Despite the lack of detailed clarifi-
cation of the molecular mechanism, these findings provided
primary evidence that targeting the clusterin gene using AS
ODN enhances apoptosis induced by p53 gene therapy for
advanced bladder cancer.
We finally investigated the effect of combined treatment
consisting of AS clusterin ODN, Ad5CMV-p53, and cisplatin
on KoTCC-1 tumor growth in vivo. Cisplatin, which has been
the most frequently used and effective chemotherapeutic
agent for bladder cancer [2], was selected based on our
previous studies showing the substantial synergistic cyto-
toxic effects of cisplatin combined with AS clusterin ODN
compared with several other agents [18,19]. Surprisingly,
established subcutaneous tumors completely regressed in 6
of 10 mice receiving this combined regimen. Moreover,
lymph node metastasis could not be observed in any mice
in which KoTCC-1 cells were orthotopically injected followed
by treatment with this combined regimen. Because the dose
of cisplatin used in these experiments was tolerable and
there were no evident side effects observed during treat-
ment, this combined treatment could be performed safely
and significant antitumor effects on bladder cancer could be
expected. It would also be of interest to investigate whether
the therapeutic effects of this regimen are further enhanced
by additional use of AS ODN targeted against other cell
survival genes, such as Bcl-2, Bcl-xL, and insulin-like growth
factor binding protein-5, which have been demonstrated to
show potential antitumor effects in our previous studies
[20,22,23].
In conclusion, the present findings identify clusterin as an
inhibitor of wild-type p53 gene therapy (i.e., p53-dependent
apoptosis), and that inhibition of clusterin gene expression
with the use of AS technology may provide a feasible and
safe strategy to enhance therapeutic efficacy of p53 gene
therapy in bladder cancer. Although it would be required to
elucidate the detailed molecular mechanism of pathophysio-
logical roles of clusterin in apoptosis signal transduction, the
preclinical data described here provide proof of principle of
support for designing clinical studies with combined AS
clusterin ODN plus Ad5CMV-p53 therapy for patients with
advanced bladder cancer.
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